Heart failure with mid-range ejection fraction: are there clinical reasons in introduction of this new group as a distinct entity?

Агеев, Ф Т; Овчинников, А Г

doi:10.18087/cardio.2609

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Профибротические процессы при ХСН связаны с окислительным, гемодинамическим и метаболическим стрессами, которые, как известно, усиливаются у пациентов с нарушением гликемического статуса [4]. Диабетическая кардиомиопатия, как правило, ассоциируется с гипертоническим и ишемическим поражением сердца, определяя по этиологической детерминанте так называемый "смешанный" клинический фенотип ХСН, в контексте которого могут встречаться как пациенты с СНсФВ, так и пациенты с СНпФВ [5]. В рамках изучения патогенетических основ развития различных фенотипов СН в настоящее время считается перспективным исследование профиля биомаркеров с акцентом на их диагностические и прогностические возможности.…”

Section: Molecular Biomarker Profile Of Heart Failure With Mid-range unclassified

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Лебедев¹,

Лясникова²,

Васильева³

et al. 2020

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To study molecular biomarkers in patients with type 2 diabetes (T2D) in combination with heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) and compare the data obtained with clinical characteristics of myocardial remodeling.Material and methods. The study included 42 patients with T2D (men — 53%, mean age — 60 years) with clinical manifestations of class II HF: 29 patients with HFpEF (group 1) and 13 patients with HFmrEF (group 2). The control group consisted of 13 healthy people, which were comparable in sex and age and had a normal body mass index (BMI). Patients received stable glucose-lowering and optimal drug therapy for HF for 3 months prior to enrollment in the study. Patients with HFpEF and HFmrEF were comparable in clinical and demographic parameters, had glycated hemoglobin (HbA ) of 8,5% and 8,8%, respectively (p>0,05), increased BMI or grade I-II obesity.We studied following biomarkers: NT-proBNP, highly sensitive C-reactive protein (hsCRP), sST2, galectin-3, procollagen type I C-terminal propeptide (PICP), matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1).Results. Volumetric parameters of the left ventricle (LV),LV mass indexed to growth and NT-proBNP were higher in the group of HFpEF patients (p<0,05 for all). The concentrations of galectin-3, PICP were higher, and the MMP-9/TIMP-1 ratio decreased in patients with T2D compared with the control group (p<0,05 for all). PICP values were higher in patients with HFmrEF compared with patients with HFpEF (106,4 (85,4; 140,4) ng/ml vs 46,8 (12,6; 98,6 ng/ml), respectively, p=0,043). In patients with T2D and HF, a relationship was found between TIMP-1 andLV end-diastolic volume (r=-0,68; p=0,042).Conclusion. Patients with HFmrEF and T2D have higherLV volume and mass, higher concentrations of NT-proBNP and PICP in comparison with patients with HFpEF. The direction of MMP-9/TIMP-1 changes may reflect a decrease in antifibrotic processes. Further prospective studies on large samples using a multiple biomarker model are required in T2D and various HF phenotypes.

show abstract

Section: Molecular Biomarker Profile Of Heart Failure With Mid-range unclassified

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Лебедев¹,

Лясникова²,

Васильева³

et al. 2020

Russ J Cardiol

View full text Add to dashboard Cite

show abstract

“…South Russian Journal of Therapeutic Practice 2020;1(3):44-53 Обсуждение В представленном исследовании пациенты, перенесшие ОДСН, характеризуются высокой коморбидностью и сочетанием нескольких причин формирования ХСН (АГ, ИБС, СД 2 типа, ФП) одновременно у одного пациента. В других отечественных и зарубежных исследованиях также показано, что для современного пациента с ХСН характерна высокая коморбидность, что приводит к изменению клинического «портрета» современного пациента с ХСН [5,8,19,20,21,22]. Такие причины, как хроническая ревматическая болезнь сердца, перенесенные миокардит и инфекционный эндокардит, являются редкими среди этиологических факторов ХСН.…”

Section: южно-российский журнал терапевтической практикиunclassified

“…Эпидемиологические исследования последних лет свидетельствуют о значительном росте распространенности хронической сердечной недостаточности (ХСН) и увеличении бремени этого заболевания, связанных с ростом коморбидности и постарением населения [1,2,3,4]. Успехи в лечении заболеваний, являющихся этиологией ХСН, привели к росту распространенности их в популяции и формированию феномена коморбидного больного, у которого наравне с ХСН присутствуют и артериальная гипертония (АГ), ишемическая болезнь сердца (ИБС), фибрилляция предсердий (ФП) и прочие состояния [5,6]. Вышеперечисленные тенденции способствуют изменению клинического течения ХСН у современных больных [7,8] и требуют создания специальных условий оказания медицинской помощи для данной категории пациентов.…”

Section: Introductionunclassified

Rationale of specialized medical care for patients with chronic heart failure in the Russian Federation

Фомин

Vinogradova

2020

jour

View full text Add to dashboard Cite

Objectives: to determine the causes of ineffective observation and poor prognosis in patients undergoing ADHF, in real clinical practice and to consider the basics of the formation of specialized medical care for patients with heart failure (HF).Materials and methods: the study was conducted based on the City Center for the treatment of heart failure (center HF), N. Novgorod. The study consistently included 942 patients with heart failure (HF) at the age of 18 years and older who underwent ADHF and received inpatient treatment in center HF between March 4, 2016 and March 3, 2017. Based on the decisions of patients to continue outpatient monitoring in center HF, two groups of patients were distinguished: patients who continued to be monitored in center HF (group I, n = 510) and patients who continued to be monitored in outpatient clinics at the place of residence (group II, n = 432). The assessment of adherence to treatment, overall mortality, survival and re-admission to a depth of two years of observation was carried out. Statistical data processing was performed using Statistica 7.0 for Windows and the software package R.Results: all patients in the study groups had high comorbidity. Group 2 patients turned out to be statistically significantly older, more often had III functional class (FC) HF, lower the baseline test score of 6-minute walk, and higher the baseline clinical assessment scale. After 2 years of follow-up in group II, there was a significant deterioration in adherence to basic therapy of HF compared with group I. According to the results of multifactorial proportional risk Cox models, it was shown that observation of patients in the group 1 is an independent factor increasing the risk of overall mortality by 2.8 times by the end of the second year of observation. Survival after two years of follow-up was: in group I — 89.8 %, and in group II — 70.1 % of patients (OR = 0.3, 95 % CI 0.2 – 0.4; p1/2 < 0.001). After two years of follow-up, the proportion of re-hospitalized patients in group II was greater (78.0 % of patients) versus group 1 (50.6 % of patients, OR = 3.5, 95 % CI 2.6 – 4.6; p1/2 <0.001). The independent risk of re-hospitalization according to multinominal logit regression was 3.4 times higher in group II and 2.4 times for III – IV FC HF. Conclusions: the inclusion of patients with HF in the system of specialized medical care improves adherence to treatment, prognosis of life and reduces the risk of repeated hospitalizations. Patients of an older age and with an initially greater clinical severity refused specialized supervision in center HF.

show abstract

“…Выделение больных с промежуточной ФВ в отдельную группу послужило стимулом к проведению научных исследований в отношении их групповых особенностей, закономерностей патофизиологии и специфики лечения. Однако клиническая, лабораторная и патофизиологическая характеристика подобной группы на сегодняшний день ограничена [1,2].…”

Section: Introductionunclassified

Clinical and pathogenetic features of chronic heart failure with mid-range ejection fraction

Шляхтина

Антоненок

Галанцев

2021

SJCEM

View full text Add to dashboard Cite

show abstract

Heart failure with mid-range ejection fraction: are there clinical reasons in introduction of this new group as a distinct entity?

Cited by 8 publications

References 17 publications

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

Rationale of specialized medical care for patients with chronic heart failure in the Russian Federation

Clinical and pathogenetic features of chronic heart failure with mid-range ejection fraction

Contact Info

Product

Resources

About